Introduction
Gaucher disease, the most common lysosomal storage disorder in humans, is caused by the absence of ␤-glucocerebrosidase (GC; EC 3.2.1.45). This disease offers an attractive model for studying retroviral stem cell gene therapy since GC deficiency is caused by a single gene defect and the cells primarily affected are cells derived from the pluripotent hemopoietic stem cell (PHSC). Treatment of Gaucher disease by allogeneic bone marrow transplantation or enzyme supplementation therapy has proven successful. From bone marrow transplantation studies it is known that significant clinical benefit can be obtained in Gaucher patients with as little as 20-30% healthy donor cells. 1 Unfortunately, current retroviral stem cell gene therapy technology is not sufficient to reach such high in vivo levels of corrected peripheral blood cells. With the current generation of retroviral vectors transduction of PHSCs is at the level of 0.01-5%. [2] [3] [4] One approach to increase the number of vector-positive cells in the peripheral blood and thus GC expression levels, encompasses the construction of bicistronic retroviral vectors containing an internal ribosomal entry site (IRES) ensuring co-ordinated expression of two cDNAs. [5] [6] [7] In such bicistronic vectors, both cDNAs are transcribed as one mRNA and thus selection on the basis of the dominant selectable marker will result in increased numbers of
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Received 27 February 1998; accepted 8 May 1998 cells positive for the therapeutic protein. If the dominant selectable marker confers resistance towards myelosuppressive drugs, in particular drugs that can be administered in vivo at low concentrations for prolonged periods in humans without inducing secondary toxicity, then the need for severe myeloablative treatment during gene therapy procedures might be avoided. This is of particular interest in the treatment of relatively benign disorders such as Gaucher disease for which a safe and effective, albeit expensive, enzyme replacement therapy is available. Studies in which a methotrexate (MTX)-resistant DHFR cDNA was introduced into the bone marrow of mice, have clearly shown that: (1) infusion of mouse bone marrow transduced with an MTX-resistant DHFR into irradiated syngeneic recipient mice provided protection against otherwise lethal MTX concentrations; [8] [9] [10] and (2) cells responsible for the long-term repopulation of the mouse hemopoietic system were transduced and protected against otherwise lethal MTX concentrations since protection was transferred to secondary and even tertiary bone marrow transplant recipients. 10 These experiments unambiguously showed that murine PHSCs were transduced, expressed the mutant DHFR protein and were protected against high concentrations of MTX suggesting that selection for transduced cells may take place.
This article describes the generation and characterization of amphotropic bicistronic retroviruses containing a human glucocerebrosidase (hGC) cDNA and a human dihydrofolatereductase (hDHFR) cDNA. The hDHFR gene was mutated resulting in an amino acid substitution of phenylalanine to serine at codon position 31 which renders the DHFR protein 10 000-fold more resistant to MTX. 11 
Results

Retroviral constructs
In construct IG-GC10 transcription of the hGC and hDHFR cDNA is under the control of the wild-type Moloney murine leukaemia virus (MoMLV) long terminal repeat (LTR). In the 3′-LTR of IG-GC12 the wildtype MoMLV enhancer in U3 is replaced by a mutant polyoma enhancer (⌬Mo+PyF101). [12] [13] [14] The hDHFR cDNA was obtained from liver RNA and the Phe31Ser mutation was introduced through site-specific mutagenesis. This mutation renders the DHFR protein 10 000-fold more resistant to MTX. 11 Besides the desired Phe31Ser mutation, complete DNA sequencing of the hDHFR cDNA revealed the presence of a second mutation, Leu158Pro, in our hDHFR cDNA. This Leu158-Pro mutation has been identified previously 15 and we therefore assume that this mutation is a normal but rare human polymorphism. In constructs IG-GC10 and IG-GC12 all transcriptional elements such as initiation sites for first-and second-strand synthesis, polyadenylation, splice donor and splice acceptor sites are identical (Figure 1 ).
Generation and characterization of recombinant virus producers
Ecotropic packaging cells (⌿-CRE) were transfected, in duplicate, with 20 g of IG-GC10 or IG-GC12 plasmid DNA. Following transfection, transfectants were selected by culturing the cells in DMEM medium containing 10% dialysed serum and 0.15 m MTX until parental ⌿-CRE cells died. Cell culture supernatant from the transfected, MTX selected ⌿-CRE cells was used to repeatedly infect the amphotropic retroviral producer cells PA317. The cells were selected using 0.15 m MTX. To demonstrate that the presence of 0.15 m MTX results in increased DHFR and GC expression levels, total RNA was extracted from both selected and nonselected IG-GC12 ecotropic and amphotropic producer pools. The results, shown in Figure 2a , clearly demonstrate that upon selection with MTX expression levels of both hGC and hDHFR were increased. The increase in mRNA levels correlated with increased GC enzymatic activity (Figure 2b ). From the MTX-resistant amphotropic pools cloned retroviral producer cells were obtained using a cloning method previously described. 16 The clones finally selected were coded PA110 (IG-GC10) and PA125 (IG-GC12).
To test the integrity of the proviral structure of IG-GC10 and IG-GC12, genomic DNA was extracted from infected and MTX selected amphotropic PA317 cells. Isolated DNA was digested with NheI which liberates the complete proviral structure since NheI is present in both LTRs. Since Southern analysis revealed only one DNA fragment of the expected length with both an hGC or an hDHFR probe we concluded that both IG-GC10 and IG-GC12 are present intact in the selected amphotropic producer pools (Figure 3 ). Genomic DNA extracted from the cloned retroviral producer cell lines (PA110 and PA125) was also digested with SpeI, an enzyme unique in the proviral structure (see Figure 3 ). Southern analysis of this genomic DNA with an hGC probe revealed two independent ecotropic virus integrations in PA110 and one in PA125 (data not shown). It is known that the mutant polyoma enhancer ⌬Mo+PyF101 is not very active in mouse fibroblasts and therefore wild-type revertants may arise (L Kaptein, unpublished data). Therefore, we determined whether the PyF101 enhancer was still present after cloning the retrovirus producer cell lines to exclude the possibility that we cloned a producer cell lacking the PyF101 enhancer. For this purpose, genomic DNA from both cloned producer cell lines PA110 and PA125 were digested with SstI or NheI. Southern analysis using a 200 bp PyF101 probe yielded a 800 bp DNA fragment (SstI) or a 4750 bp fragment (NheI) in PA125 cells only. We therefore conclude that the PyF101 enhancer is present in both LTRs of PA125 (data not shown).
In vitro selection of transduced primary Gaucher type II fibroblasts Virus supernatants derived from the cloned amphotropic retroviral producer cell lines PA110 and PA125 were used to infect Gaucher type II fibroblasts. To mimic a low transduction protocol, the virus used was diluted fivefold in regular medium before infection. In all experiments, a retroviral vector identical to PA125 but containing only the hGC cDNA (PA2) 14 was used as a control for MTX selection. Forty-eight hours after infection a small number of cells was used to determine the initial transduction efficiency whereas the bulk of the cells was reseeded either in normal DMEM medium or in 0.15 m MTX selection medium. Selection proceeded for 2 weeks during which PA2-infected Gaucher fibroblasts died. In Figure 4 results are shown of both GC activity and the percentage of GC + cells determined 48 h after infection and after 2 weeks with or without MTX selection. The results demonstrate that: (1) at a concentration of 0.15 m MTX, endogenous wild-type DHFR expression is insufficient to protect Gaucher type II fibroblasts since cells infected with a single hGC vector died; (2) MTX selection results in a three-to six-fold increase in GC activity proving coselection of GC; and (3) compared with the GC activity measured 48 h after infection there was no GC activity increase without MTX selection, indicating that selection of retrovirus-transduced cells occurs. To con- Figure 1 ).
firm that the GC + Gaucher type II fibroblasts as determined by flow cytometry are the cells containing the proviral structure, fibroblasts were infected with five-fold diluted PA110 and PA125 virus after which GC + and GC − cells were sorted. From both the GC + and GC − fractions equal numbers of cells were subjected to PCR analysis for the provirus. Subsequent Southern blotting confirmed the presence of the PA110 or PA125 provirus predominantly in those cell fractions that are positive for GC activity as determined by flow cytometry ( Figure 5 ).
Function of bicistronic retroviral vectors under high MTX selection pressure
To determine the effect of MTX selection pressure on GC expression and thus indirectly the stability of the bicistronic constructs once integrated, infected cells were subjected to a range of MTX concentrations. For this purpose Gaucher type II fibroblasts were infected once with PA110, PA125 or (control) PA2 virus. Forty-eight hours after infection, cells were split and seeded in six-well plates in medium containing increasing concentrations of MTX (range 0-45 m). Selection proceeded for 2 weeks during which PA2 infected cells died, except for those cultured in the absence of MTX. Both PA110 and PA125 infected fibroblasts showed normal growth kinetics in the presence of 45 m MTX. An increase in GC activity up to 10-fold was achieved as compared with infected, nonselected fibroblasts ( Figure 6 ). The GC activity as measured in PA110 and PA125 infected, unselected Gaucher type II fibroblasts is comparable with the GC activity as measured in normal human fibroblasts (data not shown), indicating that in infected and selected fibroblasts GC activity is 10-fold higher than normal. The above described data suggest that the integrated provirus is stable under high MTX selection pressure. To confirm provirus stability at the molecular level, Gaucher type II fibroblasts were infected with undiluted virus supernatant derived from PA110 and PA125. Forty-eight hours after infection, cells were cultured in MTX concentrations ranging from 0 to 200 m. Again, fibroblasts infected with PA2 virus died, except for those cultured in the absence of MTX. PA110 infected fibroblasts showed normal growth kinetics up to a MTX concentration of 80 m, and died at MTX concentrations exceeding 160 m. PA125 infected cells showed normal growth kinetics up to a MTX concentration of 60 m, and died at MTX concentrations exceeding 120 m. Genomic DNA was isolated and digested with NheI followed by Southern analysis to determine the effect of the MTX concentration on the number of proviral copies per cell. Analyses using both an hGC or an hDHFR probe indicated that: (1) the polyoma IRES facilitated sufficient translation of the mutant hDHFR cDNA to resist Ͼ100 m MTX since no aberrant provirus fragments hybridizing with the hDHFR probe were detectable; (2) an increase in the concentration of MTX resulted in an increase of the number of proviral copies per cell from 0.5 copies per cell in infected nonselected Gaucher type II cells up to an average of four (PA110) or 16 (PA125) copies per cell in infected, selected cells as determined with a phosphor imager irrespective of the probe used (hGC or hDHFR) ( Figure 7) ; and (3) using a complete hDHFR cDNA as probe, six different endogenous DHFR bands were obtained after Southern analysis (data not shown). By comparing the ratio of the signal intensities between endogenous DHFR fragments and the various lanes, endogenous DHFR amplification could be excluded since the ratios in the endogenous DHFR fragments were identical between all genomic DNA samples isolated from cells cultured under different MTX concentrations.
In vitro selection of hemopoietic cell lines Since PA110 and PA125 were developed for in vitro and in vivo selection of retrovirus-transduced hemopoietic bone marrow cells, we tested the concept in two hemopoietic cell lines, human TF-1 and K562 cells. The percentages of retrovirus-transduced GC + TF-1 and K562 cells after 2 weeks in culture with or without 0.15 m MTX are shown in Table 1 . From the results we concluded that: (1) MTX resistance was transferred to TF-1 and K562 cells upon infection with both PA110 and PA125 since noninfected or PA2-infected parental TF-1 and K562 cells died; (2) the presence of 0.15 m MTX resulted in a three-fold increase in the percentage of GC + cells for TF-1 cells from ±15% without MTX to ±45% with MTX (value at +FDGlu minus value at +FDGlu + CBE); (3) for K562 cells only a slight GC increase could be observed (±48% without MTX to ±55% with MTX); and (4) a fixed concentration of CBE of 10 m was insufficient to inhibit completely FDGlu activity in both infected and noninfected TF-1 and K562 cells. The latter could be caused by high levels of nonlysosomal ␤-glucosidase activity or a CBE concentration which is too low for these cell types. The results obtained with the flow cytometer are in agreement with GC activity measurements using a colorimetric assay for lysosomal GC and Southern analysis on genomic DNA isolated from infected and MTX selected and nonselected TF-1 and K562 cells (Figure 8 ). The observation that after transduction and MTX selection K562 cells only show a moderate increase in GC activity and number of GC active cells may be due to relatively weak LTR activity in these cells but sufficient for conferring MTX resistance. Other explanations could be down-regulation of endogenous expression upon transduction with a GC expression construct or endogenous MTX resistance arising on a baseline of MTX resistance during the first days after transduction and selection.
In vitro selection of murine bone marrow cells To confer MTX resistance to primary hemopoietic cells, bone marrow cells (BMCs) from male CBA/ca mice were transduced with PA125 retrovirus using a 72 h cocultivation procedure. After transduction murine BMCs were seeded in DMEM supplemented with either normal or dialysed serum and a MTX concentration ranging from 0 to 5 m. After 5 days in culture, cells were harvested after which an equal volume of cells cultured under different MTX concentrations was seeded in 2 ml of methylcellulose to obtain progenitor (CFU)-derived colonies. The rest of the cells were subjected to flow cytometric analysis to determine the percentage of GC + cells. To discard irradiated retroviral PA125 producer cells from analysis flow cytometry was combined with antibody CD11a which reacts with the ␣ L subunit of LFA-1, a heterodimeric surface glycoprotein expressed on all murine leukocytes. The percentage of GC +
/CD11a
+ cells upon infection, as well as the colorimetric determination of GC activity in transduced nonadherent murine BMCs (without selection) is shown in Figure 9 . These results clearly demonstrate that upon transduction increased numbers of GC + cells were obtained resulting in increased GC activity as compared with nontransduced murine BMCs. To test whether PA125-transduced mouse BMCs had become resistant to MTX the number of CFUs obtained per volume after 5 days of MTX selection was determined. Figure 10a shows the correlation between the MTX concentration employed during the first 5 days after transduction and the percentage of myeloid progenitors obtained. During the 5 day culture on MTX dia- lysed serum was added to the DMEM medium. Figure  10b shows that after 5 days of MTX selection increased numbers of hGC-positive cells are present which implies selection for retrovirus-transduced murine bone marrow cells in line with decreased MTX sensitivity. Taken together, the results described above demonstrate that: (1) we conferred MTX resistance to Gaucher fibroblasts, human hemopoietic cell lines and murine bone marrow cells; (2) MTX resistance was associated with increases in GC activity or with increases in percentages of hGC + cells in a murine background; and (3) both PA110 and PA125 bicistronic vectors are stable since under high MTX selection pressure the constructs remained intact.
Discussion
The relative success of many hemopoietic stem cell gene therapy protocols in rodents and nonhuman primates is determined by the use of marrow ablative treatments since this ensures successful engraftment and outgrowth of reinfused, ex vivo manipulated stem cells. 2, 17 However, a clinically relevant stem cell gene therapy protocol for a benign disease such as Gaucher disease, calls for avoidance of myeloreduction. To avoid marrow ablative treatment, a drastic increase in the initial retroviral transduction in combination with a selective in vivo growth advantage of provirus positive cells is required to overcome the low engraftment and lack of preferential outgrowth of ex vivo manipulated stem cells in the recipient.
To increase the initial retroviral transduction efficiency into PHSCs a number of strategies are under investigation, including in vivo cytokine-mediated priming of bone marrow cells before harvesting, alternatives for conventional 'static' retroviral gene transfer, alternative viral vectors and ex vivo maintenance and proliferation of CD34
− PHSCs. 4 A number of studies have been reported that show successful protection of murine PHSCs against myelosuppresive drugs upon transduction with a drug resistance gene. 10, 18, 19 Most of these studies employed vectors carrying a drug-resistant DHFR cDNA with the aim of protecting the bone marrow against myelotoxicity of MTX during treatment of solid tumors. Obviously for Gaucher disease one needs to show that selection for DHFR can result in selection for hGC-positive cells when using a construct carrying a second cDNA, namely the hGC cDNA. To investigate the development of myeloablation or myeloreduction-free gene therapy for Gaucher disease we generated bicistronic recombinant retroviruses carrying the hDHFR and the hGC cDNA. DHFR was chosen since mutants of hDHFR exist which provide effective resistance towards MTX, 20 a myelosuppressive drug which can be administered in vivo at low dosages for long periods of time without significant secondary toxicity in humans. 21, 22 The latter is a prerequisite for treatment of Gaucher patients. The Phe31Ser mutation employed in this study is known to render the human DHFR protein 10 000-fold more resistant towards MTX. 11 Besides the introduced
Figure 6 Stable GC activity in infected Gaucher fibroblasts even at high MTX concentrations. PA110-or PA125-infected Gaucher type II cells (GtII(PA110) or GtII(PA125)) were cultured for 2 weeks in the presence of 0-45 m MTX. Of each cell culture, 20 g of total protein was used to determine the specific hGC activity (nmol/h/mg protein) using a colorimetric assay for GC.
Phe31Ser mutation, DNA sequencing revealed a second mutation in the cDNA that we derived from normal human liver, Leu158Pro. This mutation has been identified before and therefore we assume that this mutation is a normal human polymorphism. 15 Retroviral vectors containing an hDHFR cDNA with only the Leu158Pro mutation did not render cells resistant to MTX as compared with mock-infected cells (data not shown). However, since we did not perform parallel studies in which to compare our double mutant hDHFR with a hDHFR containing only the Phe31Ser mutant, we are at present unable to speculate whether the Leu158Pro mutation has any additional effect to the Phe31Ser mutation as far as MTX resistance is concerned. Clearly, from these studies it can be deduced that our double mutant hDHFR cDNA functions as expected, ie high MTX resistance and apparently sufficient biological function.
In our bicistronic vectors the hGC cDNA was cloned upstream of the IRES fragment since it is known that expression of the gene cloned downstream of the IRES is 25-100% compared with expression of a gene cloned in the upstream position. This is dependent on the gene sequence used and on the number of stop codons present in the construct. 7 The bicistronic recombinant amphotropic retroviruses described here confer resistance towards concentrations of MTX exceeding 100 m on primary Gaucher fibroblasts. Both constructs, IG-GC10 and IG-GC12, were stable once integrated since no aberrant DHFR sequences were detectable after Southern analysis and no endogenous DHFR amplification occurred. This implies that translation of the second gene was sufficient using the polyoma IRES. Increased MTX concentrations correlated with elevated levels of GC activity and resulted in increased average numbers of retroviral copies per cell, indicating that in vitro MTX selection resulted in survival of retrovirus-transduced cells. Most likely a selection for cells that have multiple expressing integrations has occurred although we cannot exclude that the construct as a whole has been amplified during exposure of the infected cells to high MTX concentrations. We decided to construct retroviral vectors with or without a mutant polyoma enhancer (PyF101) in the 3′-LTR. Previous studies performed in our laboratory with retroviral vectors containing the mutant PyF101 enhancer have shown that the presence of this enhancer guarantees sustained expression in primitive primate PHSCs. 2 Moreover, the presence of this enhancer is known to abolish leukemogenicity of MoMuLV 23, 24 giving an added safety feature. We compared PA110 (−⌬Mo+PyF101) and PA125 (+ ⌬Mo+PyF101) to investigate whether there are differences in protein expression levels in transfected or infected murine (⌿CRE, PA317) and human cells (TF-1, K562, Gaucher type II fibroblasts). The data presented, show that in all these cell types there is no detectable difference between PA110 and PA125 in terms of expression, except for when selection is performed at high concentrations of MTX. In the latter case PA125 infected cells exhibit higher copy numbers per cell. This suggests that under these conditions an otherwise undetectable expression difference becomes apparent calling for higher levels of DHFR expression. Since for in vivo studies PA125 is preferred due to the added safety features of the ⌬Mo+PyF101 enhancer we tested this virus on murine bone marrow cells. These transduction data show that MTX resistance and increased GC expression were obtained in murine mouse bone marrow cells and therefore confirm the functionality of this bicistronic construct in primary hemopoietic cells. Several vectors utilizing the hGC cDNA and an IRES element have been reported previously. [25] [26] [27] One of the first studies demonstrated co-ordinated expression of hGC and MDR1 upon transfection into NIH/3T3 cells. 25 The use of MDR1 as a dominant selectable marker for in vivo selection has several disadvantages: (1) Zaboikin and Schuening 28 demonstrated that in Hela cells alternative splicing of a major part of the 5′ sequence of the wildtype MDR1 gene resulted in inefficient translation of the second gene since expression of the second gene (neomycin resistance) was undetectable. However, in canine CTAC cells in which the alternative MDR1 splicing does not occur second gene translation was efficient. Therefore, the authors postulated that the 5′-coding region of the MDR1 cDNA might affect IRES functioning; 28 (2) drug protection using the wild-type MDR1 cDNA can be obtained only by overexpression of the wild-type P-glycoprotein since there is significant expression of wild-type MDR1 in PHSCs. In general, protein overexpression results in less efficient protection as compared with drug-resistant mutants; and (3) myelosuppressive drugs for MDR1 protection are far more toxic than MTX making it impossible to administer drugs frequently for prolonged periods in human patients without inducing secondary toxicity. For these three reasons wild-type MDR1 is not as attractive as a dominant selectable marker in a bicistronic vector as compared with DHFR for the development of a gene therapy protocol for Gaucher disease. Other studies in which the hGC cDNA and an IRES were employed have shown expression of both hGC cell surface antigens (CD24; expressed on human B cells but absent on human stem cells, or murine heat stable antigen (HSA). 23, 24 CD24/HSA expression is only useful in determining overall transduction efficiency, in vitro infection in hemo-poietic subsets of bone marrow cells, and sorting of transduced cells in vitro before reinfusion. However, in vivo selection cannot be performed. The vectors described in this report can be used for both in vivo and in vitro selection. For this reason, and in the absence of a clinically applicable in vitro expansion system for true PHSCs, we believe that the bicistronic vectors described in this article have clear advantages over the previously reported bicistronic vectors for Gaucher disease.
Figure 8 Specific GC activity in PA125-infected TF-1 and K562 cells. , GC activity in nonselected parental TF-1/K562 cells; , GC activity in PA125-infected TF-1/K562 cells, 2 weeks after infection and cultured in the absence of MTX; , GC activity in PA125-infected TF-1/K562 cells, 2 weeks after infection and cultured in the presence of MTX. Also shown is the result of Southern analysis with a GC probe on genomic DNA extracted from PA125-infected TF-1 and K562 cells 2 weeks after infection and cultured with or without MTX. The expected length of the provirus is 4.75 kb. The 3 kb fragment represents an endogenous GC fragment since it is also present in parental TF-1 and K562 cells (data not shown).
In summary, we have developed bicistronic retroviral vectors in which the hGC and hDHFR cDNAs are linked via an IRES. These retroviral vectors were shown to be effective vectors for selection in vitro of retrovirus-transduced murine and human primary cells and cell lines. Based on these results our recombinant bicistronic vectors show promise for an in vivo selection approach which ultimately aims at a gene therapy protocol for the treatment of Gaucher disease devoid of marrow ablative treatment.
Materials and methods
Generation of Phe31Ser hDHFR cDNA Oligo (dTex)-primed (Qiagen, Germany), single-stranded cDNA was synthesised using 5 g of total human liver RNA and MMLV reverse transcriptase (BRL, Breda, The Netherlands), according to instructions supplied by the manufacturer. This cDNA was used as template for the amplification of hDHFR cDNA using oligonucleotide DHFR1 (5′-cccaagcttcccgggctgcagcgccaccatggttggttcgta aactg-3′) and DHFR2 (5′-ccatcgatctcgagtcattcttctcatat acttcaaa-3′). From the amplified 570 bp hDHFR cDNA 1 ng was used as template in a second PCR reaction which aimed at introducing a T to C base transition at nucleotide position 91. For this purpose two complementary oligonucleotides containing the desired mutation were generated: DHFR 3 (5′-caggaatgaaTCTagatatttc-3′) and DHFR4 (5′-gaaatatctAGAttcattcctg-3′). The base transition was introduced by PCR as described. 29 Sequencing of the mutant DHFR cDNA revealed two mutations as compared with wild-type human DHFR; the introduced Phe31Ser mutation and a Leu158Pro mutation.
Construction of retroviral vectors
Retroviral vector IG-GC10 contains a hGC cDNA with a 400 bp 3′-untranslated region which is linked to the DHFR cDNA by a 700 bp IRES sequence derived from the poliovirus 5′-noncoding region 5 which was kindly provided by Dr N Sonenberg (McGill University, Montreal, Canada). IG-GC10 was generated by cloning the 700 bp IRES fragment into the HindIII and EcoRV sites of pBluescript. The complete 1.9 kb hGC cDNA, retrieved from pIG-GC1 was cloned into the XhoI site of pBluescript upstream of the IRES fragment. An AvaIdigested DHFR cDNA was cloned into the AvaI site of pBluescript, downstream of the IRES fragment. With BamHI, a fragment containing the 3′ part of hGC, the IRES and the complete DHFR cDNA was recovered from pBluescript and this fragment was subsequently cloned into a BamHI-digested IG-GC1 vector, thereby completing IG-GC10. To obtain IG-GC12, a retroviral construct containing a mutant PyF101 enhancer element in the 3′-LTR, an NheI fragment of IG-GC10 containing the hGC and hDHFR sequence was cloned into an NheI-digested pBl⌬Mo(PyF101) vector (Figure 1 ). All constructs were verified by dideoxy nucleotide sequencing of the cloning boundaries and were found to be identical to the expected nucleotide sequence.
Cell culture and virus production ⌿CRE (ATCC CRL-1858; Rockville, MD, USA), PA317 (ATCC CRL-9078), K562 (ATCC CCL-243), TF-1 (ATCC CRL-2003), primary Gaucher type II fibroblasts (Coriell, Camden, NJ, USA; GM01260), and human fibroblast-like stroma were routinely maintained in DMEM supplemented with 10% heat-inactivated fetal calf serum (Gibco, Breda, The Netherlands). Recombinant ecotropic hGC virus producing cell lines were generated by transfecting 20 g IG-GC10, or IG-GC12 DNA using calcium phosphate precipitation (Life Technologies, Breda, The Netherlands). Forty-eight hours later cells were split in DMEM supplemented with 10% dialysed serum (Life Technologies) and 0.15 m MTX (Sigma, Zwijndrecht, The Netherlands). Following 10 days of MTX selection filtered (0.45-m pore size) virus supernatant from the ecotropic pools was used to infect the amphotropic packaging cell line PA317. Of the MTX selected PA317 pools, virus producing cell clones were isolated by performing two rounds of limiting dilution (Ͻ1 cell per well) in 96-well tissue culture plates as described previously. 16 The selected retrovirus producer cell clones were coded PA110(B1A3) (amphotropic, IG-GC10) and PA125(B3D12) (amphotropic, IG-GC12). Virus supernatant was harvested, filtered (0.45-m pore size), divided into aliquots, and stored at −80°C. The absence of replication-competent retrovirus (RCR) was tested by monitoring reverse transcriptase (RT) activity using a fluorimetric RT assay in infected NIH/3T3 target cells by passaging infected cells three times (data not shown).
hGC activity and flow cytometric analysis Flow cytometric analysis for the presence of GC enzyme activity using fluorescein-di-␤-glucopyranoside (FDGlu) has been described elsewhere. 30 In addition to the described GC cytometric analysis, cells were also stained with cell surface markers CD11a or CD11b to determine GC activity in hemopoietic subsets. Determination of in vitro GC activity in infected cells was performed as described previously. 16, 31 Flow cytometric analysis specific for primate GC has been described elsewhere. 32 Nucleic acid analysis Isolation of high molecular weight DNA was performed according to Stewart et al 33 and the DNA isolation procedure for PCR analysis was performed according to van Beusechem et al. 2 PCR analysis on transduced cells was performed directly using this suspension. Oligonucleotides GCo4 (5′-cagcccatgttctaccac-3′) and IRo2 (5′-cgataccgtcgacctcg-3′) were used to detect the presence of the IG-GC10 and IG-GC12 proviral constructs. RNA extraction, electrophoresis and blotting procedure was performed using standard procedures. 29 Transduction of murine hemopoietic bone marrow cells CBA/ca mice were obtained from Harlan (Zeist, The Netherlands). Bone marrow cells (BMC) were isolated by flushing the femora of 8-week-old CBA/ ca mice. BMC were seeded at a concentration of 1 × 10 6 cells per ml DMEM/10% FCS supplemented with 10 ng/ml mIL-3 and 10 ng/ml hIL-1␣. For optimal transduction, polybrene was added at a concentration 0.4 g/ml. Cocultivation transduction was performed as described previously. 34 Before addition of the murine BMC, producer cells were irradiated (20 Gy, 0.70 Gy/min, 137 Cs gammarays). After 72 h, BMC were harvested by trypsinisation and seeded in equal numbers in DMEM supplemented with mIL-3 and hIL-1␣ and either normal or dialysed FCS. MTX was added at various concentrations (range 0-5 m MTX). After 5 days, transduced and nontransduced murine BMCs, cultured in the absence of MTX, were counted. Based on these cell counts a volume corresponding to 10 4 and 10 5 cells was seeded in 2-ml Methocult 3430 (Stem Cell Laboratories, Vancouver, Canada) to obtain CFUs. To determine the effect of MTX on cell survival, identical volumes of cells cultured in the presence of MTX as compared with cells cultured in the absence of MTX, were seeded in Methocult. Also, murine BMCs selected for 5 days with MTX were subjected to flow cytometric analyses specific for hGC to determine the percentage of hGC + cells.
